ClinicalTrials.gov
ClinicalTrials.gov Menu

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00968968
Recruitment Status : Completed
First Posted : August 31, 2009
Last Update Posted : May 22, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 30, 2018
  Actual Study Completion Date : March 30, 2018